GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
|
|
- Posy Lindsey
- 5 years ago
- Views:
Transcription
1 GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
2
3 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED A1C DECREASED APPETITE REDUCED WEIGHT (OR MINIMIZED WEIGHT GAIN) REDUCED GLYCEMIC VARIABILITY HAD LOW RISK OF HYPOGLYCEMIA WITH POTENTIAL CARDIOPROTECTIVE BENEFITS WOULD YOU DO IT?
4 OBJECTIVES OVERVIEW OF DIABETES DEFECTS OVERVIEW OF DIABETES TREATMENT ALGORITHM REVIEW MECHANISM OF ACTION OF GLP-1 RA REVIEW OF AVAILABLE GLP-1 RA CASE STUDIES
5
6 ADA TREATMENT ALGORITHM
7 GLP-1 IS RESPONSIBLE FOR THE INCRETIN EFFECT= THE RELEASE OF MORE INSULIN BECAUSE OF HIGH BLOOD GLUCOSE AFTER A MEAL
8 INCRETIN MIMETICS Synthetic analog of exendin-4, a gila monster salivary polypeptide that mimics incretin and promotes glucose dependent insulin secretion, suppresses glucagon, suppresses hepatic glucose output and slows gastric emptying (reducing appetite)
9
10 INCRETIN MIMETIC Lowers HbA1c 0.6% - 1.4% Main Benefits Common adverse effects Improves blood glucose control without weight gain, promotes weight loss by decreasing appetite Diarrhea, nausea, vomiting Cautious Use Risk for pancreatitis, renal failure Contraindications Hypersensitivity, Renal impairment with CrCl < 30 ml/min, do not use liraglutide in patients with a history of or family history of medullary thyroid cancer. Do not use with DPP-4 inhibitors
11 GLP-1 FORMULATIONS
12 TWICE DAILY
13 EXENATIDE (BYETTA) (2005) Drug Mechanism of action Dosing Pharmcokinetics Side effects How supplied Exenatide (Byetta) Promotes proliferation of beta-cells & islet-cell neogenesis from precursor cells Pen injection: 5 mcg first month, 10 mcg next month if tolerated. Twice daily, within 60 minutes before first meal and evening meal, at least 6 hours apart Peak plasma concentration in 2-3 hours detectable up to 6 hours after administration Hypoglycemia with sulfonylureas, nausea, vomiting, dizziness, feeling jittery, headache, pancreatitis, constipation, headache, injection site reaction 5 mcg Prefilled pen, 10 mcg Prefilled pen
14 ONCE DAILY
15 LIRAGLUTIDE (VICTOZA) (2009) Drug Mechanism of Action Dosing Pharmacokinetics Side effects How supplied Liraglutide (Victoza)?increase beta-cell mass; improved biphasic insulin secretion Pen injection: 0.6-mcg qd x 1 week then 1.2 mcg qd if no excessive nausea. Can increase to 1.8 mcg if needed. Peak plasma concentrations in 8-12 hours Hypoglycemia with sulfonylureas, nausea, vomiting, dizziness, feeling jittery, headache, pancreatitis, constipation, headache, injection site reaction 18 mcg/3 ml Prefilled pen
16 LIXISENATIDE (ADLYXIN) 2016 Drug Mechanism of Action Dosing Pharmacokinetics Side effects How supplied Lixisenatide (Adlyxin)? Preservation of beta-cell mass Inject one hour before the first meal of the day Starting dose 10mcg SC daily x 14 days (green pen)then increase to 20mcg SC daily Peak plasma concentrations in hours Nausea, vomiting, constipation, headache, injection site irritation Starter dose (green pen) 50mcg/mL= 14 does of 10mcg/dose: Maintenance dose 100mcg/mL (burgundy pen)= 14 20mcg doses 3ml prefilled pens
17 ONCE WEEKLY
18 EXENATIDE ER [BYDUREON (BCISE)] (2012) Drug Mechanism of Action Dosing Pharmacokinetics Side effects How supplied Bydureon (Exenatide ER) (same as exenatide) 2 mg once weekly injection Any time of the day with or without food Reaches therapeutic levels after 2 weeks; at 6-7weeks reaches maximum concentration Hypoglycemia with sulfonylureas, nausea, vomiting, dizziness, feeling jittery, headache, pancreatitis, constipation, headache, injection site reaction, possible antibody formation 2mg in 0.85ml 4 count carton
19 ABLIGLUTIDE (TANZEUM) 2014 Drug Mechanism of action Dosing Pharmacokinetics Side effects How supplied Abliglutide (Tanzeum) 30 mg once weekly may increase to 50 mg once weekly Mean plasma concentration reached in 3-5 days and steady state in 3-5 weeks 30mg and 50mg
20 DULAGLUTIDE (TRULICITY) (2014) Drug Dosing Phamacokinetics Side effects How supplied Dulaglutide (Trulicity) Initial dose 0.75mg SC once weekly; may increase to 1.5mg once weekly Any time of the day Peak plasma levels in hours Nausea, vomiting and diarrhea 4 single dose pens
21 SEMAGLUTIDE (OZEMPIC) (2017) Drug Dosing Pharmacokinetics Side effects How supplied Start at 0.25mg/week x 4 weeks and increase to 0.5mg/ week x 4weeks can increase to 1mg if needed Any time of the day; with or without food Peak plasma levels 1-3 days GI side effects 0.25 & 0.5mg one prefilled pen (2mg)= 1.5mL 1mg 2 prefilled pens (4mg)= 3mL
22 COMBINATIONS
23 INSULIN + GLP-1 SOLIQUA 100/33 (GLARGINE 100/LIXISENATIDE 33MCG PER ML) USING <60UNITS OF BASAL OR LIXISENATIDE IF <30 UNITS/DAY --START WITH 15 UNITS (15GLARGINE/5MCG LIXISENATIDE); UNITS/DAY START 30 UNITS MAX DOSE 60 UNITS (60G/20 LIXISENATIDE) ONE HOUR PRIOR TO 1 ST MEAL SUPPLIED IN 3ML PREFILLED PENS
24 INSULIN + GLP-1 XULTOPHY 100/3.6 (100 UNITS DEGLUDEC/3.6 MG LIRAGLUTIDE USING LESS THAN 50 UNITS BASAL OR LIRAGLUTIDE < 1.8 STARTING DOSE 16 UNITS (16 UNITS DEGLUDEC/0.58MG MAX DOSE 50 UNITS (50 UNITS DEGLUDEC/1.8MG LIRAGLUTIDE INDEPENDENT OF FOOD SUPPLIED IN 3ML PREFILLED PENS
25 NEW AND NOVEL
26 ORAL GLP-1 RA ORAL SEMAGLUTIDE PIONEER STUDY ORAL FORMULATION OF SEMAGLUTIDE COMBINED WITH ABSORPTION ENHANCER DOSES 2.5,5,10,20, 40MG REDUCED A1C BY % SIDE EFFECTS: NAUSEA, VOMITING DIARRHEA
27 IMPLANTABLE GLP-1 RA ITCA 650 (FREEDOM TRIAL) OSMOTI MINIPUMP PROVIDING CONTINUOUS INFUSION OF EXENATIDE 20MCG/ DAY X 12 WEEKS THEN 60MCG/DAY CONTINUOUS DELIVERY FOR 3-6 MONTHS DECREASED A1C 2.8% SIDE EFFECTS: NAUSEA, VOMITING, DIARRHEA DECREASES OVERTIME
28 OVERVIEW OF CVOTS OF GLUCOSE-LOWERING DRUGS 1 SAVOR-TIMI 53 2 (n=16,492) 1,222 3P-MACE EXAMINE 3 (n=5380) 621 3P-MACE ORIGIN 6 (n=12,537) 3P-MACE TECOS 5 (n=14,671) P-MACE AleCardio 7 (n=7226) 3P-MACE DEVOTE 10 (n=7637) 3P-MACE CARMELINA 15 (n=8300) 4P-MACE + renal TOSCA IT25 (n=3371) 4P-MACE CAROLINA 16 (n=6041) 631 4P-MACE OMNEON 17 (n=4000) 4P-MACE DPP-4 inhibitor SGLT-2 inhibitor GLP1 RA Insulin PPAR agonist TZD ELIXA 4 (n=6068) 805 4P-MACE EMPA-REG OUTCOME 8 (n=7028) 691 3P-MACE LEADER 9 (n=9341) 611 3P-MACE SUSTAIN-6 11 (n=3297) 3P-MACE FREEDOM CVO 13 (n=4000) 4P-MACE CANVAS-R 12 (n=5820) Albuminuria EXSCEL 18 (n=14,000) P-MACE CANVAS 14 (n=4339) 420 3P-MACE TIMINGS REPRESENT ESTIMATED COMPLETION DATES AS PER CLINICALTRIALS.GOV STELLA-LONG TERM 22 (n=11,412) 3P-MACE + Tumors HARMONY Outcomes 24 (n=9400) 3P-MACE REWIND 20 (n=9622) P-MACE CREDENCE 21 (n=4200) Renal + 5P-MACE 1. JOHANSEN OE ORIGIN NCT NCT NCT SCIRICA BM ET AL LINCOFF AM ET AL NCT NCT NCT WHITE WB ET AL ZINMAN B ET AL NCT NCT NCT PFEFFER MA ET AL MARSO SP ET AL NCT NCT NCT GREEN JB ET AL NCT NCT NCT NCT DECLARE-TIMI (n=17,150) P-MACE Ertugliflozin CVOT 23 (n=3900) 3P-MACE
29 COMPARISON OF AVAILABLE GLP-1 RA Drug Weight loss A1c lowering Cardiovascular benefits Exenatide (Byetta) Exenatide ER (Bydureon, Bcise) ( %) + (HR-0.91) + Liraglutide (Victoza) + ++( %) ++ (HR= 0.87) ++ Dulaglutide (Trulicity) Lixisenatide (Adlyxin) Semaglutide (Ozempic) + ++( %) Ongoing trial (1.1%-combo) - (HR=1.02) ( %) ++ (HR=0.74) + GI side effects
30 CASE STUDIES
31 A CASE FOR GLP-1INHIBITORS INITIAL PRESENTATION B. J. IS A 65 YEAR OLD FEMALE WITH A >20 YEAR H/O T2DM PMH: CAD, HTN, HLD, CKD, OBESITY (BMI-41) MEDICATIONS: LANTUS UNITS AT HS, HUMALOG 5-10 UNITS WITH MEALS, ACTOS 15MG DAILY LABS: SMBG MG/DL (AVG 207MG/DL); A1C 8.6% VITALS: WEIGHT-243#, BP 131/61,HR-71
32 A CASE FOR GLP-1 (CONT) FOLLOW-UP B.J. RETURNS TO CLINIC AFTER 4-5 MONTHS MEDICATIONS: HUMALOG 2-4 UNITS (OCC.), ACTOS 15MG QD, LIRAGLUTIDE 1.8MG/D LABS: SMBG (AVG 128)MG/DL, A1C 7.5% VITALS: WEIGHT-236#, BP- 130/68, HR-67
33 CASE # 2 HM IS A 45 YEAR OLD MALE WITH A 8 YEAR H/O T2DM PMH: HTN, HYPERLIPIDEMIA, OBESITY (BMI 33) CURRENT MEDICATIONS: LANTUS 40 UNITS DAILY, NOVOLOG 10 UNITS TIDAC, GLIMIPERIDE 4MG BID AND TRADJENTA 5MG LABS: A1C 8.9%, BG READINGS MG/DL, LDL- 158MG/DL VITALS: BP 153/100, 85, WEIGHT 232# HE REPORTS MISSING HIS LANTUS DOSE 3-4 TIMES A WEEK. HE DOES NOT TAKE HIS NOVOLOG BECAUSE HE HATES SHOTS
34 CASE #2 (CONT) 3 MONTHS LATER MEDICATIONS: LANTUS 40 UNITS, NOVOLOG 12 UNITS TIDAC, TRADJENTA 5MG LABS: BG READINGS MG/DL, A1C 9.6% VITALS: WEIGHT 232#, BP 175/106 STARTED LIRAGLUTIDE
35 CASE #2 (CONT) ONE YEAR LATER MEDICATIONS: LANTUS 40 (MISSING DOSES 4X/WEEK), NOVOLOG 12 (NOT TAKING), VICTOZA 1.8 (NO MISSED DOSES) LABS: BG READINGS MG/DL, A1C 9.1% VITALS: WEIGHT 218 (BMI- 31), BP 113/74 CHANGED TO XULTOPHY
36 TAKE HOME MESSAGE
37 TAKE HOME MESSAGE GLP-1 RECEPTOR AGONISTS ARE SOME OF THE MOST WELL TOLERATED, EFFECTIVE THERAPIES IN THE BATTLE AGAINST TYPE 2 DIABETES. THEY ARE MORE AFFECTIVE IN PROMOTING WEIGHT LOSS AND LOWERING A1C THAN METFORMIN, DDP-4 INHIBITORS AND SULFONYLUREAS GLP-1 RAS ARE SYNERGISTIC WITH SGLT-2 INHIBITORS, METFORMIN AND INSULIN KEEP IN MIND THAT THE PRIMARY GOAL OF DIABETES MANAGEMENT IS THE MITIGATION OF CARDIOVASCULAR EVENTS.
38 SPECIAL THANKS THOMAS BERG, MS LILLY TOBY DAMRON, PHARMD-NOVONORDISK
39 QUESTIONS???
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationBasal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January
Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More information2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists
WAYNE STATE UNIVERSITY COLLEGE OF PHARMACY & HEALTH SCIENCES FEBRUARY 28, 2016 The Evolving Armamentarium for Type 2 Diabetes: Clinical Assistant Professor, Department of Pharmacy Practice Ambulatory Care
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: LA.PST.14 Effective Date: 03.18 Last Review Date: 3.18 Line of Business: Medicaid Revision Log 1Revision Log 1Revision
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationIndividualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD
Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationExploring Non-Insulin Therapies in Type 1 Diabetes. Objectives. Pre-Assessment Question #1. Disclosures
Exploring Non-Insulin Therapies in Type 1 Diabetes Disclosures Dr. Cornell: Advanced Practitioner Advisory Board and Speakers Bureau: Novo Nordisk Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationWelcome to the PHASE Learning Community! October 31, 2018
Welcome to the PHASE Learning Community! October 31, 2018 Webinar Housekeeping 1. Dial in for audio: 303-248-0285, Access Code: 5617817 2. Lines are muted. You can chat in questions or unmute your line
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationKeep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018
Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets Nicole.pezzino@wilkes.edu
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationDR. SUBHASH K. WANGNOO
Photograph DR. SUBHASH K. WANGNOO M.D, D.M, FRCP (London) Senior Consultant, Endocrinologist & Diabetologist Apollo Centre for Obesity, Diabetes and Endocrinology Indraprastha Apollo Hospital, Sarita Vihar,
More informationWhat's Hot in Diabetes Care Fred Toffel, MD, FACP, FACE
What's Hot in Diabetes Care 2018 Fred Toffel, MD, FACP, FACE Objectives A Taste of Technology Updates on Continuous Glucose Monitoring Smart Insulin Pumps Connected Insulin Pens Getting to the Heart of
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationGLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Linda Burns Learning Outcomes Understand the place of injectible therapies in diabetes Understand when patients may require insulin therapy Consider
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
Learning Objectives Understand and appropriately individualize treatments based on evidencebased guideline recommendations across the continuum of care in patients with T2DM Key = Clinical Pearl Identify
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More informationDrug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists
Texas Vendor Drug Program Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Publication History Developed February 2006. Revised September 2018; September 2016; June 2015; October 2013; December
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationRebecca Newberry APRN MS CDE
Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationWITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE
UPDATE ON THE NEW DIABETES MEDICATIONS AND HOW TO INCORPORATE INTO YOUR PRACTICE Amy DeGueme, MD, ECNU Madison Medical Affiliates 3/15/19 WITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE Which ones to
More informationThe Role of Combination or Coformulation. Treatment of Type 2 Diabetes
The Role of Combination or Coformulation Products in the Treatment of Type 2 Diabetes Jennifer M. Trujillo, PharmD, FCCP, BCPS, CDE, BC-ADM University of Colorado Skaggs School of Pharmacy and Pharmaceutical
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More information